KR20230009478A - Lnp023의 결정질 형태 - Google Patents

Lnp023의 결정질 형태 Download PDF

Info

Publication number
KR20230009478A
KR20230009478A KR1020227043301A KR20227043301A KR20230009478A KR 20230009478 A KR20230009478 A KR 20230009478A KR 1020227043301 A KR1020227043301 A KR 1020227043301A KR 20227043301 A KR20227043301 A KR 20227043301A KR 20230009478 A KR20230009478 A KR 20230009478A
Authority
KR
South Korea
Prior art keywords
lnp023
hydrochloride
disease
crystalline hydrate
hydrate form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227043301A
Other languages
English (en)
Korean (ko)
Inventor
지첸 지아
필립 루스텐버거
마리 마이어
마시모 모라토
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Priority to KR1020257009662A priority Critical patent/KR20250048392A/ko
Publication of KR20230009478A publication Critical patent/KR20230009478A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020227043301A 2020-05-18 2021-05-17 Lnp023의 결정질 형태 Pending KR20230009478A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257009662A KR20250048392A (ko) 2020-05-18 2021-05-17 Lnp023의 결정질 형태

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063026637P 2020-05-18 2020-05-18
US63/026,637 2020-05-18
US202063052699P 2020-07-16 2020-07-16
US63/052,699 2020-07-16
PCT/IB2021/054225 WO2021234544A1 (en) 2020-05-18 2021-05-17 Crystalline form of lnp023

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257009662A Division KR20250048392A (ko) 2020-05-18 2021-05-17 Lnp023의 결정질 형태

Publications (1)

Publication Number Publication Date
KR20230009478A true KR20230009478A (ko) 2023-01-17

Family

ID=76076387

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227043301A Pending KR20230009478A (ko) 2020-05-18 2021-05-17 Lnp023의 결정질 형태
KR1020257009662A Pending KR20250048392A (ko) 2020-05-18 2021-05-17 Lnp023의 결정질 형태

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257009662A Pending KR20250048392A (ko) 2020-05-18 2021-05-17 Lnp023의 결정질 형태

Country Status (10)

Country Link
US (3) US11603363B2 (https=)
EP (1) EP4153580A1 (https=)
JP (3) JP7592743B2 (https=)
KR (2) KR20230009478A (https=)
CN (4) CN120168469A (https=)
AU (2) AU2021276912B2 (https=)
CA (1) CA3180829A1 (https=)
IL (1) IL297975A (https=)
TW (2) TW202504893A (https=)
WO (1) WO2021234544A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3675854T1 (sl) 2017-08-31 2025-05-30 Novartis Ag Derivati piperidinil-indola za uporabo v zdravljenju glomerulopatije c3
TW202504893A (zh) * 2020-05-18 2025-02-01 瑞士商諾華公司 Lnp023之結晶形式
US11951101B2 (en) 2020-07-16 2024-04-09 Novartis Ag Methods of using factor B inhibitors
WO2022143940A1 (zh) * 2020-12-30 2022-07-07 南京明德新药研发有限公司 一系列哌啶取代的苯酸类化合物及其应用
EP4333845A1 (en) * 2021-05-07 2024-03-13 Novartis AG Iptacopan for the treatment of atypical hemolytic uremic syndrome
WO2022264101A1 (en) 2021-06-18 2022-12-22 Novartis Ag Method of treating an autoimmune hematological disorder
CA3248808A1 (en) 2022-03-04 2023-09-07 Novartis Ag USE OF IPTACOPAN FOR THE TREATMENT OF LUPUS NEPHROPATHY
JP7849520B2 (ja) * 2022-06-30 2026-04-21 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 含窒素架橋複素環誘導体の薬学的に許容される塩、結晶形及びその調製方法
EP4669321A1 (en) 2023-02-23 2025-12-31 Novartis AG METHODS OF USING FACTOR B INHIBITORS
CN121712505A (zh) 2023-08-25 2026-03-20 诺华股份有限公司 使用因子b抑制剂的方法
WO2025148628A1 (zh) * 2024-01-10 2025-07-17 河北以岭医药研究院有限公司 哌啶基吲哚衍生物及其制备方法和应用
WO2025172910A1 (en) 2024-02-16 2025-08-21 Novartis Ag Factor b inhibitors for treatment of anca-associated vasculitis
WO2026003809A1 (en) * 2024-06-29 2026-01-02 Assia Chemical Industries Ltd. Solid state forms of iptacopan hydrochloride

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds
KR20130086534A (ko) 2010-06-01 2013-08-02 플러스 케미칼스, 에스.에이. 익사베필론의 고체 형태
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
MX2018007392A (es) 2015-12-23 2018-08-15 Greenovation Biotech Gmbh Polipeptidos para inhibir la activacion del complemento.
SI3675854T1 (sl) 2017-08-31 2025-05-30 Novartis Ag Derivati piperidinil-indola za uporabo v zdravljenju glomerulopatije c3
TW202504893A (zh) * 2020-05-18 2025-02-01 瑞士商諾華公司 Lnp023之結晶形式

Also Published As

Publication number Publication date
JP2024150466A (ja) 2024-10-23
JP2026048795A (ja) 2026-03-17
JP7592743B2 (ja) 2024-12-02
AU2021276912B2 (en) 2023-12-14
CN120168469A (zh) 2025-06-20
WO2021234544A1 (en) 2021-11-25
AU2024201640B2 (en) 2025-10-09
KR20250048392A (ko) 2025-04-08
IL297975A (en) 2023-01-01
CN120208923A (zh) 2025-06-27
TW202204335A (zh) 2022-02-01
TWI858258B (zh) 2024-10-11
US20230265067A1 (en) 2023-08-24
US11603363B2 (en) 2023-03-14
JP7789850B2 (ja) 2025-12-22
AU2021276912A1 (en) 2022-11-24
TW202504893A (zh) 2025-02-01
EP4153580A1 (en) 2023-03-29
CA3180829A1 (en) 2021-11-25
AU2024201640A1 (en) 2024-04-04
CN115667240B (zh) 2025-04-22
CN120172955A (zh) 2025-06-20
JP2023518552A (ja) 2023-05-02
CN115667240A (zh) 2023-01-31
US20250270186A1 (en) 2025-08-28
US12384758B2 (en) 2025-08-12
US20210371394A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
KR20230009478A (ko) Lnp023의 결정질 형태
US20250188054A1 (en) Crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
WO2020228746A1 (en) Crystalline forms of n- (5- (5- ( (1r, 2s) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide
US12590095B2 (en) Crystalline forms of an orally available, selective kit and PDGFR kinase inhibitor
EP3887356B1 (en) Multi-component crystals of an orally available hif prolyl hydroxylase inhibitor
RU2818684C1 (ru) Кристаллическая форма lnp023
CA3080657A1 (en) Crystalline salt of a tricyclic poly(adp-ribose) polymerase inhibitor

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20221209

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20221209

Comment text: Request for Examination of Application

PG1501 Laying open of application
A302 Request for accelerated examination
PA0302 Request for accelerated examination

Patent event date: 20240409

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240619

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20241223